Clinical Trial Update: Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel [Phase 2]

View source ↗

Summary

Phase 2 trial to determine the maximum tolerated dose and safety of PEP005 Topical Gel (ingenol mebutate) for actinic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• PEP005 Topical Gel (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Keratosis | Phase 2 | Status: COMPLETED